Bavarian Nordic A/S (VIE:BAVA)

Austria · Delayed Price · Currency is EUR

25.69

+0.28 (1.10%)

At close: Dec 4, 2025

0.71% (1Y)

Market Cap	1.99B
Revenue (ttm)	922.11M
Net Income (ttm)	327.37M
Shares Out	n/a
EPS (ttm)	4.13
PE Ratio	6.09
Forward PE	17.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	25.43
Previous Close	25.41
Day's Range	25.43 - 25.69
52-Week Range	17.92 - 32.52
Beta	n/a
RSI	41.58
Earnings Date	Mar 12, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1992

Employees 1,605

Stock Exchange Vienna Stock Exchange

Ticker Symbol BAVA

Full Company Profile

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.